Fertility
Fertility app to pay US$200K after sharing sensitive user data
Premom developer has been accused of deceiving users by sharing their personal information

The US fertility and ovulation-tracking app Premom will pay US$200,000 to settle claims that it shared highly sensitive user data with third parties.
Premom, a free app that helps women track ovulation, periods, and other health information, encourages users to provide information about their menstrual cycles, fertility, and pregnancy and import their data from other apps and devices.
Its developer, Easy Healthcare, has been accused by the Federal Trade Commission of deceiving users by sharing their personal information with two China-based firms and other third parties and sharing sensitive health data with AppsFlyer and Google.
The FTC did not disclose the names of the firms that got hold of the sensitive information, but said they had been “flagged for suspect privacy practices”.
The agency has said the Illinois-based company did not notify consumers of the unauthorised disclosures as required under the Health Breach Notification Rule.
The data Easy Healthcare shared with third parties “revealed highly sensitive and private details about Premom’s users and led to the unauthorised disclosure of facts about an individual user’s sexual and reproductive health, parental and pregnancy status, as well as other information about physical health conditions and status,” the FTC has added.
Samuel Levine, director of the FTC’s Bureau of Consumer Protection, said: “Premom broke its promises and compromised consumers’ privacy.
“We will vigorously enforce the Health Breach Notification Rule to defend consumer’s health data from exploitation. Companies collecting this information should be aware that the FTC will not tolerate health privacy abuses.”
According to the complaint, Premom failed to encrypt adequately the data it shared with third parties, including those in China, subjecting this data to potential interception or seizure.
The FTC has announced a proposed order that would have Easy Healthcare pay a US$100,000 civil penalty for violating the Health Breach Notification Rule and another US$100,000 to Connecticut, the District of Columbia and Oregon, for violating their respective laws.
Easy Healthcare Corporation, the FTC has said, would be barred from sharing users’ health data with third parties for advertising, required to obtain users’ consent before sharing health data for any other purpose, and required to tell users how their personal data will be used.
Experts have previously called for greater transparency around women’s health apps, amid concerns that app developers share their users’ data for advertisement and marketing purposes and “hide” data collection practices.
A Secure Data Recovery study has recently found that women’s health applications have secured the “dishonourable crown” of being the least trusted applications in the US.
According to the study, “respondents were most concerned about women’s health apps tracking their data… (with) more people reported having concerns with these apps than people who actually reported using the apps”.
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Fertility
Femtech World reveals fertility innovation award shortlist

Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist

HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care

Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.

Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Events4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Fertility4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS













Pingback: The NHS data breach demonstrates the urgent need for reforming the online advertising industry- femtech can show the way - FemTech World